Cisplatin-based induction chemotherapy: Clinical Trials

4 trials of Cisplatin-based induction chemotherapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Recruiting 4

Follow Cisplatin-based induction chemotherapy: new trials by email Literature Review of Cisplatin-based induction chemotherapy trials Research Report on Cisplatin-based induction chemotherapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Cisplatin-based induction chemotherapy, Full course of PD-1 monoclonal antibody, Reduced-dose radiotherapy to CTV2 - Nasopharyngeal Carcinoma
Phase 3RecruitingMing-Yuan Chen3462025-11-202026-01-09
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy - Nasopharyngeal Carcinoma (NPC)
Phase 3RecruitingMing-Yuan Chen4562025-11-182026-01-09
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
Full course of PD-1/PD-L1 blockades, Cisplatin-based induction chemotherapy, Standard-dose IMRT - Nasopharyngeal Carcinoma, De-escalation Therapy
Phase 3RecruitingSun Yat-sen University5862024-07-302024-11-05
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT - Nasopharyngeal Carcinoma, De-escalation Therapy
Phase 3RecruitingSun Yat-sen University5042023-10-092023-12-15

Conditions studied

Nasopharyngeal Carcinoma (4)  ·  Pathologic Complete Response (2)

Sponsors

Ming-Yuan Chen (2)  ·  Sun Yat-sen University (2)

Countries

China (4)

Top investigators

Ming-Yuan Chen, MD,PhD (4)